Sugi Predict

Sugi Predict / Compounds / SCHEMBL2015310

SCHEMBL2015310

SCHEMBL2015310

CC(=O)c1nc(Cl)c2ccccc2c1O

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ EGLN1 Q9GZT9 7/20 0.59
▸ BBOX1 O75936 5/20 0.59
▸ FTO Q9C0B1 4/20 0.59
▸ KDM4E B2RXH2 2/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ MAPT P10636 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ NSD2 O96028 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ MCL1 Q07820 1/20 0.43
▸ THRA P10827 1/20 0.41
▸ THRB P10828 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.39
▸ PKM P14618 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL522787 0.84 EGLN1 (0.65) EGLN1BBOX1FTOKDM4EMEN1
SCHEMBL27773936 0.82 EGLN1 (0.59) EGLN1BBOX1FTOKMT2ATHRA
SCHEMBL2017928 0.81 EGLN1 (0.58) EGLN1BBOX1FTOKDM4ETHRA
SCHEMBL4407134 0.79 EGLN1 (0.63) EGLN1BBOX1FTOKDM4ETHRA
SCHEMBL28912438 0.79 EGLN1 (0.59) EGLN1BBOX1FTOTHRATHRB
SCHEMBL25934724 0.79 EGLN1 (0.80) EGLN1BBOX1FTOTHRATHRB
SCHEMBL9085786 0.78 EGLN1 (0.55) EGLN1BBOX1FTOKDM4EKMT2A
SCHEMBL522620 0.78 EGLN1 (0.69) EGLN1BBOX1FTOTHRATHRB
SCHEMBL523229 0.75 EGLN1 (0.61) EGLN1BBOX1FTOKDM4ETHRA
SCHEMBL523708 0.75 EGLN1 (0.58) EGLN1BBOX1FTOTHRATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680108-B2 Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors INCYTE CORPORATION (US) 2014-03-25 — — US disclosed
US-8680108-B2 Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors INCYTE CORPORATION (US) 2014-03-25 — — US disclosed
US-8680108-B2 Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors INCYTE CORPORATION (US) 2014-03-25 — — US disclosed
US-20110183985-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION 2011-07-28 — — US disclosed
US-20110183985-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION 2011-07-28 — — US disclosed
US-20110183985-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION 2011-07-28 — — US disclosed
WO-2011075630-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION (US) 2011-06-23 — — WO disclosed
WO-2011075630-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION (US) 2011-06-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183985-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS PIK3R1, PIK3R3, PIK3R2 EGLN1 1920/4885BBOX1 1732/4885FTO 3465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.